The notion of modelling an autoimmune disease can be enormously useful for the understanding of pathogenesis and the design of therapeutics. The model can of course also be a dangerous intellectual conceit: It is intended to illuminate the disease mechanisms for which we lack understanding, yet at the same time, we could not create the models without making prior assumptions, often biased ones, about the mechanisms we believe to be importantan immunological Catch 22. The term 'model' here might commonly encompass mouse or rat experiments, but also reductionist in vitro systems for examining interactions between cell-types or between cell-types and soluble factors. Although it would be enormously desirable to add in silico approaches to the in vitro and in vivo experiments, this remains somewhere in the distance for analysis of the immune system in general or autoimmunity in particular. Certainly, there are ever-increasing in silico components to the investigations, including microarray data mining and epitope prediction algorithms, yet our understanding of a system as complex as the immune system is insufficient to allow assembly of any but the most speculative computer models.
With respect to the mouse models, the spontaneous mutants, most notably the nonobese diabetic (NOD) mouse, have clearly been among the most informative. In cases where there are clear candidate genes implicated, knockout strains have offered a highly focused approach. The AIRE knockout mice are a good example of the value of this approach. In this regard, the impact of genomics on our understanding of autoimmunity has clearly been massive over the past decade, and will presumably fuel the generation of more and more pertinent models. In many other cases, there is simply insufficient information to generate the models that truly reiterate fully the genetics or pathology of the human diseases they mimic. In such cases, disease must be induced experimentally according to protocols based on current assumptions about the aetiology of the given disease. This is the immunological land of the blind where, for the time being at least, the one-eyed human is the King: note the enormous contribution to our understanding of and treatment of autoimmune disease made by the application of experimental allergic encephalomyelitis (EAE), despite the extent to which it has sometimes been derided by neurologists as giving a misleading picture of multiple sclerosis. In the not too distant future, as genome scans from the patient populations start to home in on disease genes that can be factored into the models, the old kings might need to be replaced. The primary focus of his laboratory for several years has been the generation of transgenic, humanized, disease models. Much of this work has centered on autoimmunity. Part of his teamwork is in close collaboration with Dr Rosemary Boyton's Lung Immunology Group within Imperial College, on models of respiratory disease. Before moving to Imperial College, Professor Altmann was for several years a senior scientist at the MRC Clinical Sciences Center, and before that was based at the Imperial Cancer Research Fund in London. Infectious diseases have become increasingly important and significant throughout the world over the past few years. Several trends have contributed to this: (1) the unrelenting HIV pandemic in Sub-Saharan Africa, (2) increasing antibiotic resistance, (3) increasing ease and affordability of air travel facilitating infectious disease transmission, (4) increasing threat of bioterrorism, (5) epidemics precipitated by natural disasters and (6) new and emerging diseases such as avian influenza, severe acute respiratory syndrome, West Nile encephalitis and hantavirus.
Infectious diseases
Human beings are constantly exposed to a vast array of microorganisms that cause infection. Humans have, therefore, evolved complex host defence mechanisms for protection. Microorganisms have also developed mechanisms to evade host defences such as antigen diversity, internalisation within host cells and inhibition of specific host defence mechanisms. This battle provides an unfolding drama in the arena of infectious diseases.
Developments in molecular genetics have allowed sequencing of the genome of several pathogens. This will give insights into the mechanisms of pathogenesis and help identify targets for treatment or protection against pathogens. Similarly sequencing of the human genome has identified polymorphisms that affect susceptibility to, or severity of infection and inflammation. This has allowed us to decipher some of the complexities of host-pathogen interactions and provides the catalyst for the discovery of new drug targets.
Potential new drugs identified will need extensive preclinical studies to ensure their safety and efficacy. Models mimicking human diseases are, therefore, essential for the development of these compounds. Models might be in vitro, in vivo or now, in silico. The contributions of each of these models will vary for each disease and compound.
The review articles in this issue focus on disease models of some important infectious diseases and will hopefully provide a panoramic view of novel targets which are desperately needed to help in the relentless battle of 'microbe versus humans'. 
